These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 36177825)

  • 1. In vitro activity of sulopenem against 1880 bacterial pathogens isolated from Canadian patients with urinary tract infections (CANWARD, 2014-21).
    Walkty AJ; Karlowsky JA; Baxter MR; Lagace-Wiens PRS; Adam HJ; Zhanel GG
    J Antimicrob Chemother; 2022 Nov; 77(12):3414-3420. PubMed ID: 36177825
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sulopenem: An Intravenous and Oral Penem for the Treatment of Urinary Tract Infections Due to Multidrug-Resistant Bacteria.
    Zhanel GG; Pozdirca M; Golden AR; Lawrence CK; Zelenitsky S; Berry L; Schweizer F; Bay D; Adam H; Zhanel MA; Lagacé-Wiens P; Walkty A; Irfan N; Naber K; Lynch JP; Karlowsky JA
    Drugs; 2022 Apr; 82(5):533-557. PubMed ID: 35294769
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro activity of sulopenem and comparator agents against Enterobacterales and anaerobic clinical isolates collected during the SENTRY Antimicrobial Surveillance Program.
    Maher JM; Huband MD; Blankers CG; Puttagunta S; Aronin SI; Castanheira M
    J Antimicrob Chemother; 2023 Jun; 78(6):1406-1414. PubMed ID: 37042351
    [TBL] [Abstract][Full Text] [Related]  

  • 4.
    Karlowsky JA; Adam HJ; Baxter MR; Denisuik AJ; Lagacé-Wiens PRS; Walkty AJ; Puttagunta S; Dunne MW; Zhanel GG
    Antimicrob Agents Chemother; 2019 Jan; 63(1):. PubMed ID: 30397056
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Contemporary Evaluation of Tebipenem
    Mendes RE; Arends SJR; Streit JM; Critchley I; Cotroneo N; Castanheira M
    Microbiol Spectr; 2023 Feb; 11(1):e0205722. PubMed ID: 36625644
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro activity of fosfomycin against bacterial pathogens isolated from urine specimens in Canada from 2007 to 2020: CANWARD surveillance study.
    Karlowsky JA; Baxter MR; Walkty AJ; Lagacé-Wiens PRS; Bay D; Adam HJ; Zhanel GG
    J Antimicrob Chemother; 2022 Oct; 77(11):3035-3038. PubMed ID: 35971759
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activity of ceftolozane/tazobactam against Gram-negative isolates among different infections in Hong Kong: SMART 2017-2019.
    Karlowsky JA; Lob SH; Khan A; Chen WT; Woo PCY; Seto WH; Ip M; Leung S; Wong QW; Chau RWY; DeRyke CA; Young K; Motyl MR; Sahm DF
    J Med Microbiol; 2022 Apr; 71(4):. PubMed ID: 35451945
    [No Abstract]   [Full Text] [Related]  

  • 8. In vitro susceptibility of urinary Escherichia coli isolates to first- and second-line empirically prescribed oral antimicrobials: CANWARD surveillance study results for Canadian outpatients, 2007-2016.
    Karlowsky JA; Lagacé-Wiens PRS; Adam HJ; Baxter MR; Laing NM; Walkty AJ; Zhanel GG
    Int J Antimicrob Agents; 2019 Jul; 54(1):62-68. PubMed ID: 31034938
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro activity of ceftaroline-avibactam against gram-negative and gram-positive pathogens isolated from patients in Canadian hospitals from 2010 to 2012: results from the CANWARD surveillance study.
    Karlowsky JA; Adam HJ; Baxter MR; Lagacé-Wiens PR; Walkty AJ; Hoban DJ; Zhanel GG
    Antimicrob Agents Chemother; 2013 Nov; 57(11):5600-11. PubMed ID: 23979759
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dramatic rise in the proportion of ESBL-producing Escherichia coli and Klebsiella pneumoniae among clinical isolates identified in Canadian hospital laboratories from 2007 to 2016.
    Denisuik AJ; Karlowsky JA; Adam HJ; Baxter MR; Lagacé-Wiens PRS; Mulvey MR; Hoban DJ; Zhanel GG;
    J Antimicrob Chemother; 2019 Aug; 74(Suppl 4):iv64-iv71. PubMed ID: 31505647
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Non-susceptibilities to antibiotics against important Gram-negative bacteria, and imipenem-relebactam, meropenem-vaborbactam against carbapenem non-susceptible Enterobacterales and Pseudomonas aeruginosa isolates implicated in complicated intra-abdominal and urinary tract infections in Taiwan, 2019.
    Jean SS; Lu MC; Ho MW; Ko WC; Hsueh PR;
    Int J Antimicrob Agents; 2022 Mar; 59(3):106521. PubMed ID: 35066144
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antimicrobial resistance patterns of bacterial pathogens recovered from the urine of patients at Canadian hospitals from 2009 to 2020.
    Walkty A; Karlowsky JA; Lagace-Wiens P; Baxter MR; Adam HJ; Zhanel GG
    JAC Antimicrob Resist; 2022 Dec; 4(6):dlac122. PubMed ID: 36466136
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ceftolozane/tazobactam activity tested against aerobic Gram-negative organisms isolated from intra-abdominal and urinary tract infections in European and United States hospitals (2012).
    Sader HS; Farrell DJ; Flamm RK; Jones RN
    J Infect; 2014 Sep; 69(3):266-77. PubMed ID: 24780763
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro antimicrobial susceptibility of clinical respiratory isolates to ceftazidime-avibactam and comparators (2016-2018).
    Piérard D; Stone GG
    BMC Infect Dis; 2021 Jun; 21(1):600. PubMed ID: 34162341
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro activity of ceftolozane/tazobactam versus antimicrobial non-susceptible Pseudomonas aeruginosa clinical isolates including MDR and XDR isolates obtained from across Canada as part of the CANWARD study, 2008-16.
    Walkty A; Adam H; Baxter M; Lagacé-Wiens P; Karlowsky JA; Hoban DJ; Zhanel GG
    J Antimicrob Chemother; 2018 Mar; 73(3):703-708. PubMed ID: 29244121
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro activity of plazomicin against 5,015 gram-negative and gram-positive clinical isolates obtained from patients in canadian hospitals as part of the CANWARD study, 2011-2012.
    Walkty A; Adam H; Baxter M; Denisuik A; Lagacé-Wiens P; Karlowsky JA; Hoban DJ; Zhanel GG
    Antimicrob Agents Chemother; 2014 May; 58(5):2554-63. PubMed ID: 24550325
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antimicrobial susceptibility among Gram-positive and Gram-negative organisms collected from the Latin American region between 2004 and 2015 as part of the Tigecycline Evaluation and Surveillance Trial.
    Vega S; Dowzicky MJ
    Ann Clin Microbiol Antimicrob; 2017 Jul; 16(1):50. PubMed ID: 28701170
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular epidemiology of extended-spectrum β-lactamase-, AmpC β-lactamase- and carbapenemase-producing Escherichia coli and Klebsiella pneumoniae isolated from Canadian hospitals over a 5 year period: CANWARD 2007-11.
    Denisuik AJ; Lagacé-Wiens PR; Pitout JD; Mulvey MR; Simner PJ; Tailor F; Karlowsky JA; Hoban DJ; Adam HJ; Zhanel GG;
    J Antimicrob Chemother; 2013 May; 68 Suppl 1():i57-65. PubMed ID: 23587779
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sulopenem for the Treatment of Complicated Urinary Tract Infections Including Pyelonephritis: A Phase 3, Randomized Trial.
    Dunne MW; Aronin SI; Das AF; Akinapelli K; Breen J; Zelasky MT; Puttagunta S
    Clin Infect Dis; 2023 Jan; 76(1):78-88. PubMed ID: 36068705
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro activity of ceftazidime-avibactam and comparators against Gram-negative bacterial isolates collected in the Asia-Pacific region as part of the INFORM program (2015-2017).
    Ko WC; Stone GG
    Ann Clin Microbiol Antimicrob; 2020 Apr; 19(1):14. PubMed ID: 32238155
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.